latest on PURE from gene inger's www.ingerletter.com "PURE Bioscience (PURE) was added as a speculative 'pick' recently after the firm announced an offering discussed in prior remarks. Last week we speculated as price action faded modestly from recent highs, it had provided newer reasonable entries. It rallied fairly smartly, consolidating; so may press new closing bull market highs soon. This past week, after a 15% haircut, we argued further dips (perceived as temporary scenarios) would probably invite nibbling on the buy-side no lower than the 2.50's, as that was prior to potential rallying behavior ahead of next week's upcoming New York presentation. We got that and the stock closed on Friday near 2.80 on large volume.
Most of that occurred in the hour after we posted the San Diego Union Tribune story to our MarketCast members; as soon as one of our members made us aware of it. It is a bit ironic, as the stock had traded about 150,000 shares and was solid as a rock all day, but even with that story out, sleepy readers in San Diego didn't react terribly aggressively. Shortly after we distributed it to our intraday members (newspaper; so a very public source, whether entirely accurate or slightly off in a couple minor areas as I suspect; but not materially so), it hit the major wires and the rest was history. Sellers were evident too; probably some of the smaller low-cost registrants from the filing not entirely cognizant (or in agreement) with the potential we see should they 'land' even a single major household name consumer product client. This reminds me a bit of the early days in Ionatron, where the old USH&G holders with tiny costs thought a run to 2 or 3 was terrific (and it was for them), when in reality 'critical mass' was just starting to be contemplated, not even reached. Sometimes it's not greed hanging-in-there; it's smart. If you're a long-time investor in a speculative development stage company and they finally get their act together and are off to the races, it's likely not a time to leave the track, but to relax in the 'clubhouse' and see if you actually own a thoroughbred. It is time to let it have a chance to get some 'legs' to see if it can really be a performer.
At the same time, any hints of actual corporate progress could ignite renewed interest in the shares; with the San Diego paper pretty much validating everything speculated here (even more aggressively). The company has too; if you'll review 'charts & plans' posted on the purebioscience.com website. Glimpses of where they hope to take this interesting speculative little company in the near future (we call attention to the 'more info' button on the right lower side of their homepage; and to the fairly complex need to click with symbols as provided in the series of charts and tables; care needed not to be taken to the start) are provided.
Bottom line: the registration is out of the way; thought further dips to be temporary; then the stock would start firming ahead of next week's show in New York City, which likely will introduce PURE to a number of new players there. All of this has come as it has been postulated, which is no assurance as regards the future. However, as or if it closes over 3, anticipate PURE might subsequently file for an American Exchange stock listing, and then once it eventually (given contracts) surpasses 5, institutional or other interests become feasible. It's all speculative on contracts, test markets, sales, and of course a single consumer household company (or more) taking it National. In the long-run the 'drug' filings are pertinent, but in the near-term the cleaning products are a potential big deal, and not simply another 3 a.m. infomercial situation. That's as a result of the independent validations, and primarily because of CIBA distribution (in our opinion). However, anything 'concrete' on the hospital side is a big deal too, since over 40,000 Americans die annually of staph infections alone, picked up in hospitals.
We think the 'friendlier' FDA basically is reflecting the reality that bacterial resistance to other products is a big problem, and that this type of silver ion is not yet shown to become bacterial resistant. We don't know what the future holds; but for now this will do, and we think there is going to be a lot of interest in their product mix forthcoming.
As the updated tables in the website presentation pretty much cover most of what we intended to review (and we are justly slightly busy to say the least) we may not delve into details very much again, as the company's investor relations staff has really done a great job with that slide-type (PowerPoint probably) presentation of company goals; and the San Diego Union story covers most of what I was going to add about people (in terms of the saga, the pioneers and inventors; how they got from point-to-point). It is almost as if this stock is ready to take-off, so we won't belabor the basis of original analysis, and are glad speculators had the chance to take their time buying the dips.
Here's a link to the San Diego Union Story: if you're interesting in buying (or adding) it is of note that choppy action is entirely likely; and that this is a 'bb' stock; so use care.
Though of course even a contract won't mean instant distribution; it's the first step on the way, then test markets (maybe; but maybe not for some distribution like ideally in the case of The Home Depot, since their industrial supply arm already has a year's experience with PURE) and that might be good enough for some other big retailers. It is hard to say; but we do speculate the company's at a good 'pivot point' this year.
As to that 'PowerPoint' presentation on the website, we've rarely if ever seen one so straight to the point, and not mincing words in efforts to describe a company's plans. The 'linkage' by clicking to multiple pages also is highly unusual, and shows a great deal of confidence and care went into preparing it. If the company's able to remotely execute on what's outlined, it promises a very interesting few months and years (the drug indications ultimately) coming up. It's necessary to point-out this is speculative until something is announced, but we're tempted to be optimistic given an aggressive schedule they themselves outline. Our price projections were for 3 by summer (doubt any problem with that), and ideally 4-6 later this year and then we'll see. (Opinions.)
Market Data 
Markets 
AI
